Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
Official title: A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients With Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
192
Start Date
2025-01-20
Completion Date
2025-10-02
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
DWC202404, DWC202314
\- 2 tablet, Oral, Once a day
DWC202404, DWC202314P
\- 2 tablet, Oral, Once a day
Locations (1)
Hanyang University Medical Center
Seoul, South Korea